Subject's overall satisfaction regarding control of diarrhea
Time frame · Day of survey
Use of questionnaires to assess patient satisfaction (Likert scale).
A Study to Assess Neuroendocrine Tumour (NET) Patients Currently Treated by Somatuline Autogel for History of Carcinoid Syndrome Associated With Episodes of Diarrhea
Status
Completed
Phase
Not applicable
Enrollment
340
Locations
57
Results
Not posted
Publications
1
Study summary
What the protocol is testing.
The purpose of the protocol is to to assess subject's overall satisfaction regarding control of diarrhea. The study aims to supplement results obtained through clinical trials with data obtained from a population of patients receiving treatment with Somatuline Autogel in routine practice.
Interventions
Treatment arms and agents.
No intervention details reported.
Timeline
From registration to results.
First posted
Nov 4, 2010
Study start
Oct 2010
Primary completion
Dec 2012
Study completion
Dec 2012
Results posted
Not reported
Registry updated
Nov 5, 2020
Outcomes
What the study measures.
Primary outcomes
Secondary outcomes
Impact on daily activities of the clinical manifestations of diarrhea
Time frame · Day of survey
Use of questionnaires to assess symptom severity and impact on patient's daily activities (CGI-S).
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- Not reported
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: * Out-patients 18 years of age and older, who have agreed to participate in the study * Diagnosed with a Neuroendocrine tumour (NET) and receiving treatment with Somatuline Autogel Exclusion Criteria: * Subjects for whom there are reasons that may hinder the conduct of the study (patients who have difficulty expressing themselves or who are unable to complete the questionnaires, or with insufficient data in the their files will not be enrolled in the study).
Study locations
57 registered sites.
Czechia · France · Hungary · Israel · Italy · Poland · Spain · United Kingdom. Showing up to 24 locations stored in the fast local snapshot.
Teaching Hospital Brno Bohunice
Brno, Czechia
University Hospital Hradec Kralove
Hradec Králové, Czechia
Hospital Pardubice
Pardubice, Czechia
Teaching Hospital
Pilsen, Czechia
Charles University
Prague, Czechia
Teaching Hospital Na Bulovce
Prague, Czechia
CHU Angers
Angers, France
Hôpital Avicenne
Bobigny, France
Hôpital Saint André
Bordeaux, France
CHU Trousseau
Chambray-lès-Tours, France
Hôpital Beaujon
Clichy, France
CHU Michallon
Grenoble, France
Hôpital Edouard Herriot
Lyon, France
CHU Timone
Marseille, France
Hôpital Archet 2
Nice, France
Hôpital du Haut Leveque
Pessac, France
Hôpital Robert Debré
Reims, France
CHU St Etienne
Saint-Priest, France
Hôpital Rangueil
Toulouse, France
Institut Gustave-Roussy
Villejuif, France
Semmelweis University
Budapest, Hungary
Karádi-Nagy Bt.
Pécs, Hungary
Hadasit Medical Research
Jerusalem, Israel
Ospedale Regina Apostolorum
Albano Laziale, Italy
Related trials
More studies on Lanreotide.
NCT IDStudyPhase / statusEnrollmentUpdated
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET
Camurus AB · Gastro-enteropancreatic Neuroendocrine Tumor
Phase 3
Active, not recruiting
332
2026-07
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
Crinetics Pharmaceuticals Inc. · Carcinoid Syndrome · Carcinoid
Phase 3
Recruiting
141
2026-06
Analysis of Optimal Treatment Sequencing of Surufatinib and Somatostatin Analogs in Neuroendocrine Tumors: A Retrospective Cohort Study
West China Hospital · Neuroendocrine Tumors
Not applicable
Active, not recruiting
500
2026-04
Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors
National Health Research Institutes, Taiwan · Neuroendocrine Tumors,Gastroenteropancreatic
Phase 1 / Phase 2
Recruiting
49
2026-04
Lanreotide In Polycystic Kidney Disease Study
Assistance Publique - Hôpitaux de Paris · Autosomal Dominant Polycystic Kidney Disease (ADPKD
Phase 3
Completed
159
2026-04
Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
SWOG Cancer Research Network · Pancreatic Carcinoma · Pancreatic Neoplasm
Phase 3
Recruiting
274
2026-03
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
RayzeBio, Inc. · GEP-NET · Gastroenteropancreatic Neuroendocrine Tumor
Phase 3
Recruiting
338
2026-03
Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
Crinetics Pharmaceuticals Inc. · Carcinoid Syndrome · Carcinoid
Phase 2
Completed
36
2026-03
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.